Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase
申请人:Bowers Simeon
公开号:US20080090817A1
公开(公告)日:2008-04-17
The invention provides N-cyclic sulfonamido compounds and salts of Formula I:
wherein A is as described in the specification and R
1
and R
2
combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.
Bridged N-cyclic sulfonamido inhibitors of gamma secretase
申请人:Elan Pharmaceuticals, Inc.
公开号:US07345056B2
公开(公告)日:2008-03-18
The invention provides N-cyclic sulfonamido compounds and salts of Formula I:
wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.
N-Bridged bicyclic sulfonamides as inhibitors of γ-secretase
作者:Simeon Bowers、Gary D. Probst、Anh P. Truong、Roy K. Hom、Andrei W. Konradi、Hing L. Sham、Albert W. Garofalo、Karina Wong、Erich Goldbach、Kevin P. Quinn、John-Michael Sauer、William Wallace、Lan Nguyen、Susanna S. Hemphill、Michael P. Bova、Guriqbal S. Basi
DOI:10.1016/j.bmcl.2009.10.060
日期:2009.12
The structural modification of a series of [3.3.1] bicyclic sulfonamide based gamma-secretase inhibitors is described. Appropriate substitution on the bicyclic scaffold provides a significant increase in the metabolic stability of the compounds resulting in an improved in vivo metabolic profile. (C) 2009 Elsevier Ltd. All rights reserved.